New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcyte's Vaccine Candidates -
- Sutro to Receive $22.5 Million in Upfront Payments and is Eligible for Up to an Additional $135 Million Pending Option Exercise and from Other Milestones -
https://finance.yahoo.com/news/sutro-biopharma-vaxcyte-enter-option-210500057.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.